Navigation Links
ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012
Date:1/31/2013

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign.  These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad technology platform.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

VC-01 is a very promising, development-stage product that consists of pancreatic precursor cells (called PEC-01) derived from a proprietary human embryonic stem cell line and encapsulated in a proprietary, immune isolating medical device (the ENCAPTRA® device).  When implanted under the skin in suitable animal models, the cells further differentiate into insulin producing and other endocrine cells that regulate blood glucose in a manner similar or identical to a normal pancreas.  If VC-01 performs in humans as it has in animal studies, it could effectively cure type 1 diabetics and be an important new therapy for insulin dependent type 2 diabetics.

ViaCyte's significant intellectual property portfolio now includes over 300 issued patents and pending applications related to the growth, directed differentiation and use of human pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem cells.  This portfolio includes 51 issued U.S. and foreign patents specifically directed to the Company's VC-01 product.  In addition to the protection afforded by patents, the Company also relies on significant proprietary know-how to develop its product offerings.

Dr. Paul Laikind , ViaCyte's pres
'/>"/>

SOURCE ViaCyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
2. BioSpace Spotlights Leading Life Science Community
3. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
4. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
5. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
6. Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System
7. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
8. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
9. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
10. Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012
11. Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... 11, 2008 RiverVest Venture Partners,announced today that ... Venture Fund II, L.P., with total committed capital ... which was licensed,as a Small Business Investment Company, ... tier of leverage from the Small Business Administration., ...
... CAMBRIDGE, Mass., April 11 Biopure,Corporation (Nasdaq: ... United Kingdom,s,Medicines and Healthcare products Regulatory Agency ... to be in general compliance,with the principles ... in the Commission Directives. The company received ...
... Renowned Clinic Invests in Extracranial Radiosurgery, SUNNYVALE, ... ), a global leader in the field of ... part of the renowned,Hirslanden group of private hospitals, ... System sold in Switzerland, allowing patients greater,access to ...
Cached Biology Technology:RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3Biopure Operations Compliant With U.K. Manufacturing Guidelines 2Biopure Operations Compliant With U.K. Manufacturing Guidelines 3First CyberKnife System Sold in Switzerland 2First CyberKnife System Sold in Switzerland 3First CyberKnife System Sold in Switzerland 4
(Date:8/21/2014)... pancreas digesting itself resulting in severe abdominal pain, vomiting ... 20,000 patients are diagnosed with the disease resulting in ... is restricted to intravenous fluid and nutritional support. ... Sciences, who led the research, said "The major causes ... and excessive alcohol intake combined with a high fat ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... heart having limited ability to regenerate following injury, heart disease ... developed world. Research impacting strategies for heart repair will be ... Houston (UH). Eric N. Olson, a molecular biologist ... "Heart Making and Heart Breaking: New Strategies for Heart Repair." ...
... Tampa, Fla. (May. 8, 2012) Two studies appearing ... (20:11-12), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , ... that may make them therapeutically useful and appropriate for ... immature dental pulp stem cells , A ...
... Angeles, CA (May 8, 2012) A new study from ... when men chair committees that select scientific awards recipients, males ... new study also reports that while in the past two ... scientific achievements, compared to men, they win more service and ...
Cached Biology News:New heart repair strategies discussed at UH lecture May 15 22 Cell Transplantation studies impact dental stem cell research for therapeutic purposes 22 Cell Transplantation studies impact dental stem cell research for therapeutic purposes 3Women's scientific achievements often overlooked and undervalued 2
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
...
Biology Products: